Lexicon Pharmaceuticals price to free cash flow LXRX

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 1.2×; Oct 2020
10-year median: 2.6×
10-year range: 1.2× to 12.6×
Peer median: 7.5×

Lexicon Pharmaceuticals' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Oct 2020, at 1.2×.

On the days it had one over the last ten years, its median was 2.6×, from 1.2× in Oct 2020 to 12.6× in Dec 2016.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	1.2×	1.2×	3.9×
2019	4.1×	3.4×	4.7×
2018	n/m a value too high to mean anything
2017	12.1×	10.4×	12.1×
2016	10.4×	6.6×	13.3×

Against its peers

Companies in Drug Manufacturers - General nearest Lexicon Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
LXRXLexicon Pharmaceuticals	n/m
CRMDCorMedix	2.4×
ZVRAZevra Therapeutics	17.9×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	13.8×
COLLCollegium Pharmaceutical	2.3×
ABUSArbutus Biopharma	n/m
ARVNArvinas	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
PCRXPacira BioSciences	8.1×
Peer median	7.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lexicon Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.